The ability of biomarkers to assess the severity of atopic dermatitis
Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab
Brief Report
biomarker
eotaxin-3
EASI
B-PAD
Immunologic diseases. Allergy
RC581-607
3. Good health
Atopic dermatitis
DOI:
10.1016/j.jacig.2023.100175
Publication Date:
2023-09-27T01:44:16Z
AUTHORS (44)
ABSTRACT
To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out Biomarkers Predict Clinical Improvement AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study Japan, explore AD.The aim this find associated objective and subjective clinical findings patients moderate-to-severe based on B-PAD identify sensitive enough assess severity AD.We performed as consortium composed 19 medical facilities enrolling 110 AD. evaluated Eczema Area Severity Index (EASI) assessment well Patient-Oriented Measure (POEM) numeric rating scale pruritus (pruritis-NRS) assessment, measuring at baseline.We found that 12, 6, 7 showed significant positive associations EASI, POEM, pruritis-NRS, respectively. Most either POEM or pruritis-NRS were included among EASI. Of examined, CCL26/eotaxin-3 SCCA2 most capable assessing shown by 2 kinds receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was best both again using analyses.We study. Moreover, we identified and/or having greatest ability EASI; did same pruritis-NRS. These will be useful treating
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (14)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....